Targeting HER2 in Colorectal Cancer

Manish A. Shah, MD, discusses the HERACLES clinical trial, which explored treatment with trastuzumab (Herceptin) and lapatinib (Tykerb) in patients with HER2-amplified metastatic colorectal cancer.